The first-generation ALK inhibitor Crizotinib has demonstrated some intracranial efficacy in treating NSCLC CNS metastases, as seen in the PROFILE 1014 study, but its overall effectiveness in the CNS is considered limited [89,90]. Here, ALK is linked to non-small cell lung carcinoma.